

## Clinical Policy: Satralizumab-mwge (Enspryng)

Reference Number: CP.PHAR.463

Effective Date: 08.14.20

Last Review Date: 02.22

Line of Business: Commercial, HIM, Medicaid

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Satralizumab-mwge (Enspryng<sup>™</sup>) is an anti-interleukin-6 receptor antagonist.

### FDA Approved Indication(s)

Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Enspryng is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Neuromyelitis Optica Spectrum Disorder (must meet all):

1. Diagnosis of NMOSD;
2. Prescribed by or in consultation with a neurologist
3. Age  $\geq$  18 years;
4. Member has positive serologic test for anti-AQP4 antibodies;
5. Member has experienced at least one relapse within the previous 12 months;
6. Member has a history of at least two relapses during the previous 24 months;
7. Baseline expanded disability status scale (EDSS) score of  $\leq$  6.5;
8. Failure of rituximab (*Ruxience<sup>™</sup>* and *Truxima<sup>®</sup>* are preferred) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;  
*\*Prior authorization may be required for rituximab*
9. At the time of request, member does not have active hepatitis B infection (positive results for hepatitis B surface antigen and anti-hepatitis B virus tests) or active or untreated latent tuberculosis;
10. Enspryng is not prescribed concurrently with rituximab, Soliris<sup>®</sup>, or Uplizna<sup>®</sup>;
11. Dose does not exceed 120 mg at weeks 0, 2, and 4, and every 4 weeks thereafter.

**Approval duration: 6 months**

##### B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is

NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

## II. Continued Therapy

### A. Neuromyelitis Optica Spectrum Disorder (must meet all):

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy – including but not limited to improvement or stabilization in any of the following parameters:
  - a. Frequency of relapse;
  - b. EDSS;
  - c. Visual acuity;
3. Enspryng is not prescribed concurrently with rituximab, Soliris, or Uplizna;
4. If request is for a dose increase, new dose does not exceed 120 mg every 4 weeks.

**Approval duration: 6 months**

### B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.  
**Approval duration: Duration of request or 6 months (whichever is less);** or
2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

## III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

## IV. Appendices/General Information

### *Appendix A: Abbreviation/Acronym Key*

AQP-4: aquaporin-4

EDSS: expanded disability status scale

FDA: Food and Drug Administration

NMOSD: neuromyelitis optica spectrum disorder

### *Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

| Drug Name   | Dosing Regimen   | Dose Limit/<br>Maximum<br>Dose |
|---|--|--------------------------------|
| Rituxan <sup>®</sup> /Riabni <sup>™</sup> /Ruxience <sup>™</sup> /<br>Truxima <sup>®</sup> (rituximab)* | 375 mg/m <sup>2</sup> per week for 4 weeks as<br>induction, followed by 375 mg/m <sup>2</sup><br>biweekly every 6 to 12 months | See regimen                    |

Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.

\*Off-label

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): known hypersensitivity to satralizumab or any of the inactive ingredients, active hepatitis B infection, active or untreated latent tuberculosis
- Boxed warning(s): none reported

*Appendix D: General Information*

- AQP-4-IgG-seropositive status is confirmed with the use of commercially available cell-binding kit assay (Euroimmun).

**V. Dosage and Administration**

| Indication | Dosing Regimen  | Maximum Dose |
|------------|---|--------------|
| NMOSD      | 120 mg SC at weeks 0, 2, 4, and every 4 weeks<br>thereafter | See regimen  |

**VI. Product Availability**

Solution for injection in a single-dose prefilled syringe: 120 mg/mL

**VII. References**

1. Enspryng Prescribing Information. South San Francisco, CA: Genentech, Inc.; August 2020. Available at: [www.enspryng.com](http://www.enspryng.com). Accessed September 15, 2021.
2. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. *N Engl J Med*. 2019; 381: 2114-2124.
3. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. *Lancet Neurol*. 2020; 19(5): 402-412.
4. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. *European Journal of Neurology*. 2010; 17: 1019–1032.

**Coding Implications**

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| HCPCS Codes | Description                       |
|-------------|-----------------------------------|
| C9399       | Unclassified drugs or biologicals |

| HCPCS Codes | Description            |
|-------------|------------------------|
| J3590       | Unclassified biologics |

| Reviews, Revisions, and Approvals  | Date     | P&T Approval Date |
|--|----------|-------------------|
| Policy created   | 01.21.20 | 02.20             |
| 1Q 2021 annual review: drug is now FDA approved - criteria updated per FDA labeling: added requirement that member does not have active HBV or TB since both are contraindications; added requirement against concurrent use with rituximab, Soliris, or Uplizna; references to HIM.PHAR.21 revised to HIM.PA.154; updated HCPCS codes; references reviewed and updated. | 09.29.20 | 02.21             |
| 1Q 2022 annual review: no significant changes; specified that Truxima is also a preferred rituximab product; references reviewed and updated.  | 09.15.21 | 02.22             |

**Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene<sup>®</sup> and Centene Corporation<sup>®</sup> are registered trademarks exclusively owned by Centene Corporation.